[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2016106829A - Применение ингибиторов ацетил-СоА карбоксилазы для лечения обыкновенных угрей - Google Patents

Применение ингибиторов ацетил-СоА карбоксилазы для лечения обыкновенных угрей Download PDF

Info

Publication number
RU2016106829A
RU2016106829A RU2016106829A RU2016106829A RU2016106829A RU 2016106829 A RU2016106829 A RU 2016106829A RU 2016106829 A RU2016106829 A RU 2016106829A RU 2016106829 A RU2016106829 A RU 2016106829A RU 2016106829 A RU2016106829 A RU 2016106829A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
dihydrospiro
aminoquinoline
indazole
piperidine
Prior art date
Application number
RU2016106829A
Other languages
English (en)
Inventor
Уильям Пол ЭСЛЕР
Габриэль Элизабет СОННЕНБЕРГ
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2016106829A publication Critical patent/RU2016106829A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (4)

1. Применение 1'-(2-аминохинолин-7-карбонил)-1-изопропил-4,6-дигидроспиро[индазол-5,4'-пиперидин]-7(1Н)-она или его фармацевтически приемлемой соли в изготовлении лекарственного средства для лечения акне.
2. Применение фармацевтический композиции, содержащей 1'-(2-аминохинолин-7-карбонил)-1-изопропил-4,6-дигидроспиро[индазол-5,4'-пиперидин]-7(1Н)-он или его фармацевтически приемлемую соль и по меньшей мере один фармацевтически приемлемый носитель, в изготовлении лекарственного средства для лечения акне.
3. Применение 1'-(2-аминохинолин-7-карбонил)-1-изопропил-4,6-дигидроспиро[индазол-5,4'-пиперидин]-7(1Н)-она или его фармацевтически приемлемой соли в изготовлении лекарственного средства для снижения триглицеридов секрета сальных желез, свободных жирных кислот секрета сальных желез, сложных эфиров холестерина и восковых сложных эфиров секрета сальных желез у пациента.
4. Применение фармацевтический композиции, содержащей 1'-(2-аминохинолин-7-карбонил)-1-изопропил-4,6-дигидроспиро[индазол-5,4'-пиперидин]-7(1Н)-он или его фармацевтически приемлемую соль и по меньшей мере один фармацевтически приемлемый носитель, в изготовлении лекарственного средства для снижения триглицеридов секрета сальных желез, свободных жирных кислот секрета сальных желез, сложных эфиров холестерина и восковых сложных эфиров секрета сальных желез у пациента.
RU2016106829A 2013-09-12 2014-08-29 Применение ингибиторов ацетил-СоА карбоксилазы для лечения обыкновенных угрей RU2016106829A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361877058P 2013-09-12 2013-09-12
US61/877,058 2013-09-12
PCT/IB2014/064151 WO2015036892A1 (en) 2013-09-12 2014-08-29 Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris

Publications (1)

Publication Number Publication Date
RU2016106829A true RU2016106829A (ru) 2017-10-17

Family

ID=51541122

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016106829A RU2016106829A (ru) 2013-09-12 2014-08-29 Применение ингибиторов ацетил-СоА карбоксилазы для лечения обыкновенных угрей

Country Status (17)

Country Link
US (1) US20160220557A1 (ru)
EP (1) EP3043800A1 (ru)
JP (1) JP2016534091A (ru)
KR (1) KR20160042089A (ru)
CN (1) CN105530940A (ru)
AR (1) AR097619A1 (ru)
AU (1) AU2014319990A1 (ru)
BR (1) BR112016004118A2 (ru)
CA (1) CA2923884A1 (ru)
HK (1) HK1217448A1 (ru)
IL (1) IL243969A0 (ru)
MX (1) MX2016002479A (ru)
RU (1) RU2016106829A (ru)
SG (1) SG11201600711PA (ru)
TW (1) TW201521722A (ru)
WO (1) WO2015036892A1 (ru)
ZA (1) ZA201601084B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147161A1 (en) * 2016-02-23 2017-08-31 Raju Mohan Treatment of dermatological disorders or conditions
AU2018291163B2 (en) 2017-06-30 2024-07-18 Quixgen, Inc. Novel spirolactone compounds
WO2019072478A1 (en) 2017-10-10 2019-04-18 Galderma Research & Development SPECIFIC ACETYL-COA CARBOXYLASE INHIBITORS FOR USE IN THE TREATMENT AND / OR PREVENTION OF ACNE
TW201930265A (zh) 2017-12-11 2019-08-01 西班牙商阿爾米雷爾有限公司 作為acc抑制劑的吡咯衍生物
GB201812561D0 (en) * 2018-08-01 2018-09-12 Univ Manchester Biomarkers and uses thereof
WO2020245297A1 (en) 2019-06-06 2020-12-10 Almirall, S.A. Pyrrole derivatives as acc inhibitors
WO2020245291A1 (en) 2019-06-06 2020-12-10 Almirall, S.A. Pyrrole derivatives as acc inhibitors
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
EP4014964A1 (en) 2020-12-21 2022-06-22 Almirall S.A. Topical formulation
JPWO2023090411A1 (ru) 2021-11-19 2023-05-25
US20240109915A1 (en) * 2022-07-29 2024-04-04 Pfizer Inc. Novel acc inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855897A (en) * 1996-09-13 1999-01-05 E-L Management Corp. Topical composition and method for enhancing lipid barrier synthesis
JPH11171847A (ja) 1997-09-26 1999-06-29 Fujirebio Inc ブタン酸アミド誘導体
JPH11171848A (ja) 1997-09-26 1999-06-29 Fujirebio Inc 芳香族アミド誘導体
US6120756A (en) * 1998-08-19 2000-09-19 Philip I. Markowitz Topical anionic salicylate for disorders of the skin
JP2003516938A (ja) 1999-11-12 2003-05-20 ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 細胞補酵素ａレベルの低下によって癌細胞を選択的に死滅させる方法
CA2459311C (en) * 2001-09-06 2010-08-03 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
JP2005194191A (ja) 2001-12-28 2005-07-21 Ajinomoto Co Inc 抗肥満薬、脂肪肝治療薬
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
US6485941B1 (en) 2002-04-23 2002-11-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of the carboxyltransferase component of acetyl-CoA carboxylase, and the use of such inhibition in anti-cancer and anti-lipogenic therapies
US7211423B2 (en) 2004-07-23 2007-05-01 Bristol-Myers Squibb Co. Acetyl CoA carboxylase 2 sequences and methods
WO2006017494A2 (en) 2004-08-02 2006-02-16 Elizabeth Mazzio Inhibition of anaerobic glucose metabolism
US20060178400A1 (en) 2004-11-05 2006-08-10 Beutel Bruce A Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US8299041B2 (en) 2005-04-08 2012-10-30 Isis Pharmaceuticals, Inc. Compositions and their uses directed to acetyl-CoA carboxylases
EP1911753A1 (en) 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
JP2007161630A (ja) * 2005-12-13 2007-06-28 Adeka Corp 皮脂抑制剤
JP5291471B2 (ja) 2006-02-15 2013-09-18 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
EP1999119A2 (en) 2006-02-15 2008-12-10 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
CA2648748A1 (en) 2006-04-14 2007-10-25 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
CA2668414C (en) * 2006-11-03 2015-02-10 Qlt Inc. Methods of treating dermatological disorders or conditions
KR20080052024A (ko) 2006-12-07 2008-06-11 (주)아모레퍼시픽 아세틸-조효소 ａ 카복실라제 저해활성을 갖는트리아졸로피리다진 유도체
WO2008072850A1 (en) 2006-12-11 2008-06-19 Amorepacific Corporation Triazine derivatives having inhibitory activity against acetyl-coa carboxylase
WO2008079610A2 (en) 2006-12-21 2008-07-03 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
WO2008090944A1 (ja) 2007-01-25 2008-07-31 Takeda Pharmaceutical Company Limited スピロ環化合物
EP2123652A1 (en) 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20090005375A1 (en) 2007-03-30 2009-01-01 Edcon Chang Acetyl coenzyme a carboxylase inhibitors
JP2010527360A (ja) 2007-05-14 2010-08-12 ニューエラ・ファーマシューティカルズ・インコーポレーテッド 神経細胞の代謝低下の処置のためのアセチル−ｃｏａカルボキシラーゼの阻害剤
IN2009KN04568A (ru) 2007-06-01 2015-08-28 Univ Princeton
WO2009055682A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica N.V. Crystal structure of the carboxyl transferase domain of human acetyl-coa carboxylase 2 protein (acc2 ct) and uses thereof
JP2009196966A (ja) 2008-02-25 2009-09-03 Takeda Chem Ind Ltd ピラゾリジンジオン誘導体
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US8318762B2 (en) 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
JP2011521940A (ja) 2008-05-28 2011-07-28 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
EP2307422B1 (en) 2008-07-04 2014-03-26 Msd K.K. Novel spirochromanone carboxylic acids
JP2010043019A (ja) 2008-08-12 2010-02-25 Taisho Pharmaceutical Co Ltd ピペリジニルピペラジン化合物
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
US20100113473A1 (en) 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
US20100280067A1 (en) * 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
WO2010127208A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
BR112012000254A2 (pt) 2009-07-08 2016-02-16 Dermira Canada Inc análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.
CN102695708B (zh) 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
CN101876925B (zh) 2009-11-27 2012-05-02 成都市华为赛门铁克科技有限公司 内存镜像处理方法、装置和系统
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
DE102010008644A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
DE102010008643A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
DE102010008642A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
JP2011225455A (ja) 2010-04-15 2011-11-10 Kao Corp Ｓｒｅｂｐ抑制剤
UA108102C2 (uk) 2010-04-27 2015-03-25 Біциклічні похідні і їх застосування як інгібіторів асс
US9006450B2 (en) 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
US20120129833A1 (en) 2010-08-20 2012-05-24 Bayer Pharma Aktiengesellschaft Cyclic ketoenols for therapy
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
WO2012056372A1 (en) 2010-10-29 2012-05-03 Pfizer Inc. N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
WO2012074126A1 (en) 2010-11-30 2012-06-07 Takeda Pharmaceutical Company Limited Bicyclic compound
WO2012090219A2 (en) 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
AP2013007057A0 (en) 2011-02-06 2013-08-31 Bayer Ip Gmbh (5S,8S)-3-(4'chlor-3'-fluor-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one(compound A)for treatment
WO2012108478A1 (ja) 2011-02-09 2012-08-16 武田薬品工業株式会社 単環化合物
RS54526B1 (en) * 2011-04-22 2016-06-30 Pfizer Inc. USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
DE102011080406A1 (de) 2011-08-04 2013-02-07 Bayer Pharma AG Substituierte 3-(Biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro8[4.5]dec-3-en-2-one
US20130058004A1 (en) 2011-09-01 2013-03-07 Medtronic, Inc. Feedthrough assembly including underfill access channel and electrically insulating material
WO2013035827A1 (ja) 2011-09-09 2013-03-14 塩野義製薬株式会社 新規オレフィン誘導体
US9133129B2 (en) 2011-10-24 2015-09-15 Takeda Pharmaceutical Company Limited Bicyclic compound
EP3628320B1 (en) 2011-11-11 2022-03-16 Gilead Apollo, LLC Acc inhibitors and uses thereof
EP2785690B1 (en) 2011-12-02 2016-07-13 Boehringer Ingelheim International GmbH Piperidine derivatives, pharmaceutical compositions and uses thereof
US8765959B2 (en) 2011-12-23 2014-07-01 Boehringer Ingelheim International Gmbh Piperidine derivatives
US8530461B2 (en) * 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
EP3043800A1 (en) 2016-07-20
AR097619A1 (es) 2016-04-06
SG11201600711PA (en) 2016-03-30
TW201521722A (zh) 2015-06-16
JP2016534091A (ja) 2016-11-04
KR20160042089A (ko) 2016-04-18
AU2014319990A1 (en) 2016-02-25
MX2016002479A (es) 2016-05-31
CN105530940A (zh) 2016-04-27
HK1217448A1 (zh) 2017-01-13
BR112016004118A2 (pt) 2017-10-17
IL243969A0 (en) 2016-04-21
CA2923884A1 (en) 2015-03-19
US20160220557A1 (en) 2016-08-04
ZA201601084B (en) 2017-05-31
WO2015036892A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
RU2016106829A (ru) Применение ингибиторов ацетил-СоА карбоксилазы для лечения обыкновенных угрей
MX2011008448A (es) Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
EP3143997A3 (en) Methods of administering pirfenidone therapy
HRP20240168T1 (hr) Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije
MY173215A (en) Acetylcysteine compositions and methods of use thereof
IN2014MN01755A (ru)
MX2014006947A (es) Composiciones antimicrobianas que comprenden dgla, 15-ohepa y/o 15-hetre y metodos de uso de las mismas.
CL2013002341A1 (es) Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
CA2869599C (en) Compounds which inhibit neuronal exocytosis (ii)
MX2015017202A (es) Formulacion de liberacion modificada.
FR2996838B1 (fr) Procede de preparation d'un oxyde mixte de titane et de niobium par traitement solvothermal ; electrode et accumulateur au lithium comprenant ledit oxyde mixte
IN2014MN02156A (ru)
DE602007014193D1 (de) Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
JP2012041314A5 (ru)
MX2018013474A (es) Acidos carboxilicos para aplicacion en la primera infancia.
FR2976807B1 (fr) Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
RU2016145411A (ru) Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20180911